Switching “Real-World” Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control

INTRODUCTION: The stable, ultra-long duration of action of insulin degludec (degludec) minimizes fluctuations in glucose-lowering activity over the daily (24-h) dosing period, and comparative studies with other basal insulins suggest that these properties translate into a lower risk of hypoglycemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Tentolouris, Nikolaos, Knudsen, Søren T., Lapolla, Annunziata, Wolden, Michael Lyng, Haldrup, Steffen, Schultes, Bernd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824376/
https://www.ncbi.nlm.nih.gov/pubmed/30879256
http://dx.doi.org/10.1007/s12325-019-00916-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824376/
https://www.ncbi.nlm.nih.gov/pubmed/30879256
http://dx.doi.org/10.1007/s12325-019-00916-7

Ejemplares similares